image credit- shutterstock.com
Recently, Chinese company Gan & Lee Pharmaceuticals Co., Ltd. (Gan & Lee), has launched their first Phase 1 human clinical trial for GLR2007, their in-house invented cyclic-type 4/6 kinase inhibitor (CDK4 / 6) as a potential treatment for advanced solid tumors CDK4 / 6 kinase activity is central to cell cycle regulation and plays a key role in the onset and progression of a variety of cancers.
Therefore, the company considers CDK4 / 6 to be an interesting target therapeutic agent. This Phase 1 clinical trial is a multicenter, open-label study designed to establish the safety, tolerability, and optimal dosing strategy of GLR2007 in patients with advanced solid tumors.
Dr. Lawrence Hill, CEO of Gan & Lee US, said, “Considering the encouraging pre-clinical data and the high unmet need, GLR2007 is a promising new investigational compound that could potentially address unmet medical needs in patients with advanced solid tumors. We are excited to begin this Phase 1 clinical study (NCT044427) and look forward to working with patients, caregivers, and the medical community to make a meaningful difference for people with cancer. "
